Hospital Injectable Drugs Market Growth Analysis

Market Insights

The Hospital Injectable Drugs Market is projected to grow from USD 40.64 Billion in 2021 to USD 56.51 Billion by 2028 at a CAGR of around 4.79% during the forecast period.

Wish to get a free sample? Register Here

What is a hospital injectable drug?

Hospital injectable drugs can be defined as medications which are introduced into the patient’s body with the help of injections. These drugs are injected directly into the bloodstream with the help of injectable devices such as syringes and needles.

Key Players

Key players operating in the Hospital Injectable Drugs market are-

• Baxter International Inc. (US)
• Sanofi S.A. (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• AstraZeneca plc (UK)
• Gilead Sciences, Inc. (US)
• Merck & Co., Inc. (US)
• Novartis International AG (Switzerland)
• Johnson & Johnson (US)
• Novo Nordisk A/S (Denmark)

Market Dynamics

The growth of the hospital injectable drugs market is primarily driven by an increasing number of people suffering from chronic diseases and accidental injuries. Expanding the geriatric populace across geographies is expected to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop advanced healthcare solutions is likely to create lucrative opportunities for the players operating in the global hospital injectable drugs market in the coming years

COVID-19 Impact

The COVID-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hospital injectable drugs market negatively as healthcare solutions other than COVID-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.

Wish to get a free sample? Register Here

Segment Analysis

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The market is segmented into the following categories-

By Type

• Generic Sterile Injectables
• Sterile Intravenous (IV) Solutions

By Application Type

• Cardiology & Metabolic disorders
• Neurology
• Oncology
• Autoimmune
• Gastroenterology
• Hematology
• Infectious Diseases
• Others

By End-Use Type

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce

By Region

• North America
• Asia-Pacific
• Europe
• Rest of the World

End-User Type

The market has been bifurcated into hospital pharmacy, retail pharmacy, and e-commerce. The hospital pharmacy segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and easy availability of required drugs.

Regional Analysis

North American market accounted for the largest market share in 2021 and is projected to grow at a robust CAGR during the review period. This can be attributed to the high adoption rate of advanced diagnostic equipment coupled with the presence of key market players such as Kemper Medical, Inc. (US) and Chemyx, Inc. (US). The market growth in Asia-Pacific is expected to be driven by the increasing adoption of Hospital Injectable Drugs in diagnostic procedures, particularly in developing countries.

To know which region offers the best growth opportunities, Register Here

Target Audience

Here is the list of the group of customers that the hospital inhjectable drugs market hopes to have the greatest opportunity to convert-

• Distributors
• Suppliers
• Manufacturers
• Logistics organizations
• Government bodies

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What deliverables will you get in this report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.